Skip to main content
Top
Published in: Breast Cancer Research 1/2010

Open Access 01-02-2010 | Research article

PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

Authors: Gordon C Wishart, Elizabeth M Azzato, David C Greenberg, Jem Rashbass, Olive Kearins, Gill Lawrence, Carlos Caldas, Paul DP Pharoah

Published in: Breast Cancer Research | Issue 1/2010

Login to get access

Abstract

Introduction

The aim of this study was to develop and validate a prognostication model to predict overall and breast cancer specific survival for women treated for early breast cancer in the UK.

Methods

Using the Eastern Cancer Registration and Information Centre (ECRIC) dataset, information was collated for 5,694 women who had surgery for invasive breast cancer in East Anglia from 1999 to 2003. Breast cancer mortality models for oestrogen receptor (ER) positive and ER negative tumours were derived from these data using Cox proportional hazards, adjusting for prognostic factors and mode of cancer detection (symptomatic versus screen-detected). An external dataset of 5,468 patients from the West Midlands Cancer Intelligence Unit (WMCIU) was used for validation.

Results

Differences in overall actual and predicted mortality were <1% at eight years for ECRIC (18.9% vs. 19.0%) and WMCIU (17.5% vs. 18.3%) with area under receiver-operator-characteristic curves (AUC) of 0.81 and 0.79 respectively. Differences in breast cancer specific actual and predicted mortality were <1% at eight years for ECRIC (12.9% vs. 13.5%) and <1.5% at eight years for WMCIU (12.2% vs. 13.6%) with AUC of 0.84 and 0.82 respectively. Model calibration was good for both ER positive and negative models although the ER positive model provided better discrimination (AUC 0.82) than ER negative (AUC 0.75).

Conclusions

We have developed a prognostication model for early breast cancer based on UK cancer registry data that predicts breast cancer survival following surgery for invasive breast cancer and includes mode of detection for the first time. The model is well calibrated, provides a high degree of discrimination and has been validated in a second UK patient cohort.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987, 56: 489-492.CrossRefPubMedPubMedCentral Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer. 1987, 56: 489-492.CrossRefPubMedPubMedCentral
3.
go back to reference D'Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F: Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long term follow-up that were treated in a single institution. Eur J Cancer. 2001, 37: 591-596. 10.1016/S0959-8049(00)00435-4.CrossRefPubMed D'Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F: Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long term follow-up that were treated in a single institution. Eur J Cancer. 2001, 37: 591-596. 10.1016/S0959-8049(00)00435-4.CrossRefPubMed
4.
go back to reference Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybitle JL, Elston CW: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer. 2007, 43: 1548-1555. 10.1016/j.ejca.2007.01.016.CrossRefPubMed Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybitle JL, Elston CW: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer. 2007, 43: 1548-1555. 10.1016/j.ejca.2007.01.016.CrossRefPubMed
5.
go back to reference Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle J: Reading the prognosis of the individual with breast cancer. Eur J Cancer. 2007, 43: 1545-1547. 10.1016/j.ejca.2007.04.017.CrossRefPubMed Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle J: Reading the prognosis of the individual with breast cancer. Eur J Cancer. 2007, 43: 1545-1547. 10.1016/j.ejca.2007.04.017.CrossRefPubMed
6.
go back to reference Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL: Computer Program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001, 19: 980-991.PubMed Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL: Computer Program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001, 19: 980-991.PubMed
7.
go back to reference Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of randomized trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of randomized trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef
8.
go back to reference Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of randomized trials. Lancet. 1998, 352: 930-942. 10.1016/S0140-6736(98)03301-7.CrossRef Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of randomized trials. Lancet. 1998, 352: 930-942. 10.1016/S0140-6736(98)03301-7.CrossRef
9.
go back to reference Olivoto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA: Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol. 2005, 23: 2716-2725. 10.1200/JCO.2005.06.178.CrossRef Olivoto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA: Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol. 2005, 23: 2716-2725. 10.1200/JCO.2005.06.178.CrossRef
10.
go back to reference Campbell HE, Taylor MA, Harris AL, Gray AM: An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer. 2009, 101: 1074-1084. 10.1038/sj.bjc.6605283.CrossRefPubMedPubMedCentral Campbell HE, Taylor MA, Harris AL, Gray AM: An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer. 2009, 101: 1074-1084. 10.1038/sj.bjc.6605283.CrossRefPubMedPubMedCentral
11.
go back to reference Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE, Pharoah PDP: Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?. BJC. 2009, 100: 1806-1811.CrossRefPubMedPubMedCentral Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, Caporaso NE, Pharoah PDP: Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?. BJC. 2009, 100: 1806-1811.CrossRefPubMedPubMedCentral
12.
go back to reference May S, Hosmer DW: A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Analysis. 1998, 4: 109-120. 10.1023/A:1009612305785.CrossRefPubMed May S, Hosmer DW: A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Analysis. 1998, 4: 109-120. 10.1023/A:1009612305785.CrossRefPubMed
13.
go back to reference Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA. 2004, 292: 1064-1073. 10.1001/jama.292.9.1064.CrossRefPubMed Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA. 2004, 292: 1064-1073. 10.1001/jama.292.9.1064.CrossRefPubMed
14.
go back to reference Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005, 97: 1195-1203.CrossRefPubMed Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005, 97: 1195-1203.CrossRefPubMed
15.
go back to reference Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW: Screen-detected versus symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer. 2008, 98: 1741-1744. 10.1038/sj.bjc.6604368.CrossRefPubMedPubMedCentral Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW: Screen-detected versus symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer. 2008, 98: 1741-1744. 10.1038/sj.bjc.6604368.CrossRefPubMedPubMedCentral
Metadata
Title
PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer
Authors
Gordon C Wishart
Elizabeth M Azzato
David C Greenberg
Jem Rashbass
Olive Kearins
Gill Lawrence
Carlos Caldas
Paul DP Pharoah
Publication date
01-02-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2464

Other articles of this Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine